StockNews.AI
MDGL
StockNews.AI
123 days

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

1. Madrigal Pharmaceuticals to release Q1 2025 results on May 1. 2. Live webcast scheduled for 8 a.m. ET following the financial results. 3. Rezdiffra is the first FDA-approved treatment for MASH with moderate fibrosis. 4. Ongoing Phase 3 trial for Rezdiffra evaluating MASH cirrhosis treatment.

3m saved
Insight
Article

FAQ

Why Bullish?

The announcement of financial results and the ongoing Phase 3 trial could signal growth potential, similar to prior approvals in biopharma where initial results led to price increases.

How important is it?

The upcoming earnings report and the status of Rezdiffra are crucial for investors focusing on MASH treatments.

Why Short Term?

Immediate financial results often influence stock prices quickly, as seen with other biopharmaceutical companies post-earnings.

Related Companies

GILDBMYAMGN
CONSHOHOCKEN, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its first-quarter 2025 financial results on Thursday, May 1, 2025, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. The webcast will be available approximately two hours after the live webcast. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit www.madrigalpharma.com. Investor ContactTina Ventura, IR@madrigalpharma.com Media ContactChristopher Frates, media@madrigalpharma.com

Related News